

In the claims:

Please amend the claims as follows:

Claims 1-63 (cancelled).

64. (Currently Amended) A method for monitoring treatment of a tissue comprising HSA in a patient, said method comprising:

a) administering a contrast agent to the said patient, the said contrast agent comprising ~~a physiologically compatible metal chelate~~ an organic chelating agent complexed to a paramagnetic metal ion,

wherein said organic chelating agent is selected from the group consisting of DTPA, DOTA, DTPA-BMA, and HP-DO3A;

wherein said organic chelating agent the chelate is covalently bound to a structure : -(L)_m-SDTBM either at a methyl carbon of an acetate chelating moiety of said organic chelating agent or at an ethylene carbon backbone moiety of said organic chelating agent,

wherein L is a physiologically compatible linker and wherein m can be 0 to 4;

wherein said SDTBM is a state-dependent tissue binding moiety that comprises one or more zero to six linear or branched alkyl groups having 1 to 10 carbon atoms; zero to five cycloalkyl groups; zero to five aryl groups; or heterocyclic groups or combinations thereof, wherein said alkyl, cycloalkyl, or aryl groups can be optionally and independently substituted with from 1 to 5 ether, carboxylate, or sulfate moieties;

~~the~~ said contrast agent further having:

- 1) an R1 observed value in a 4.5 wt% solution of HSA at 25 °C of greater than about 10 mM⁻¹ sec⁻¹; and
- 2) a percent binding to HSA in a 4.5 wt%, pH 7.4 solution of HSA of greater than about 10%;

- b) subjecting ~~the~~ said patient to magnetic resonance imaging to determine an initial signal intensity value in a region of interest of ~~the~~ said undesired tissue;
- c) applying an interventional therapy to at least a portion of ~~the~~ said undesired tissue in order to treat [the] said undesired tissue, ~~the~~ said interventional therapy selected from the group consisting of a thermal energy generation, a cryoablation, an injection of a denaturing liquid, an injection of a chemotherapeutic agent, and a photodynamic therapy;
- d) contemporaneously monitoring with magnetic resonance imaging a change in ~~the~~ said initial signal intensity value in ~~the~~ said region of interest of ~~the~~ said undesired tissue during ~~the~~ said interventional therapy; and
- e) stopping ~~the~~ said interventional therapy application when ~~the~~ said change in ~~the~~ said initial signal intensity value in ~~the~~ said region of interest of ~~the~~ said undesired tissue is more than about a 50% 10% reduction in ~~the~~ said initial signal intensity value.

65. (Currently Amended) The method of claim 64, wherein ~~the~~ said paramagnetic metal ion ~~complexed to the metal chelate~~ is selected from the group consisting of Gd(III), Fe(III), Mn(II), Mn(III), Cr(III), Cu(II), Dy(III), Ho(III), Er(III), Pr(III), Eu(II), Eu(III), Tb(III), and Tb(IV)[, and wherein the metal chelate comprises an organic chelating agent].

66. (Cancelled).

67. (Currently Amended) The method of claim 64, wherein said ~~the~~ organic chelating agent comprises DTPA and wherein ~~the~~ said paramagnetic metal ion ~~complexed to the metal chelate~~ is Gd(III).

68-70. (Cancelled).

71. (Currently Amended) The method of claim 64, wherein ~~the~~ said SDTBM comprises two to five ~~or more~~ cycloalkyl or aryl groups or combinations thereof and wherein ~~the~~ said two to five ~~or more~~ cycloalkyl or aryl groups or combinations thereof are arranged in a rigid, non-planar orientation.

72. (Currently Amended) The method of claim 71, wherein at least one of the said two to five ~~or more~~ cycloalkyl or aryl groups is a cyclohexyl group.

73. (Currently Amended) The method of claim 64, wherein the said R1 observed value is greater than about $20 \text{ mM}^{-1} \text{ sec}^{-1}$.

74. (Currently Amended) The method of claim 73, wherein the said R1 observed value is greater than about $30 \text{ mM}^{-1} \text{ sec}^{-1}$.

75. (Currently Amended) The method of claim 74, wherein the said R1 observed value is greater than about $40 \text{ mM}^{-1} \text{ sec}^{-1}$.

76. (Currently Amended) The method of claim 64, wherein the said percent binding to HSA is greater than about 50%.

CS 77. (Currently Amended) The method of claim 76, wherein the said percent binding to HSA is greater than about 80%.

78. (Currently Amended) The method of claim 77, wherein the said percent binding to HSA is greater than about 95%.

79. (Currently Amended) The method of claim 64, wherein the said tissue is selected from the group consisting of cancerous tissue, tumorous tissue, and neoplastic tissue.

80. (Currently Amended) The method of claim 79, wherein the said tissue is cancerous tissue.

81. (Currently Amended) The method of claim 64, wherein the said interventional therapy application is [the] said generation of thermal energy, and wherein the said thermal energy is

generated by a source selected from the group consisting of one or more focused ultrasound waves, radiofrequency waves, microwaves, and lasers.

CS 82. (Currently Amended) The method of claim 64, wherein ~~the~~ said physiologically compatible linker L is selected from the group consisting of linear alkyl, branched alkyl, cyclic alkyl, aryl, ether, polyhydroxyl, polyether, polyamine, heterocyclic, peptide, peptoid, phosphodiester, and amide moieties.

83. (Currently Amended) The method of claim 64, wherein ~~the~~ said contrast agent is selected from the group consisting of MS-315, MS-317, MS-322, MS-323, MS-325, MS-326, MS-327, and MS-328.

CE 84. (New) The method of claim 64, wherein said reduction is more than about a 50% reduction in said initial signal intensity value.
